The price of Acutus Medical Inc. (NASDAQ:AFIB) shares last traded on Wall Street rose 18.00% to $1.77.
Based on available information, 4 analysts follow Acutus Medical Inc. (NASDAQ:AFIB). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $2.50 and a low of $0.90, we find $1.70. Given the previous closing price of $1.50, this indicates a potential upside of 13.33 percent. AFIB stock price is now 84.98% away from the 50-day moving average and 79.57% away from the 200-day moving average. The market capitalization of the company currently stands at $43.67M.
Among analysts, 2 rate the stock a hold while 1 rate it a buy. Brokers who have rated the stock have averaged $1.70 as their price target over the next twelve months.
On October 22, 2021, Goldman recently initiated its ‘Neutral’ rating on the stock quoting a target price of $10, while ‘Canaccord Genuity’ rates the stock as ‘Buy’.
In other news, Huennekens R Scott, Director sold 60,000 shares of the company’s stock on Jun 03. The stock was sold for $34,800 at an average price of $0.58. Upon completion of the transaction, the Director now directly owns 507,509 shares in the company, valued at $0.9 million. Insiders disposed of 68,877 shares of company stock worth roughly $0.12 million over the past 1 year. A total of 1.90% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AFIB stock. A new stake in Acutus Medical Inc. shares was purchased by BRIDGEWAY CAPITAL MANAGEMENT, LLC during the first quarter worth $141,000. MAN GROUP PLC invested $27,000 in shares of AFIB during the first quarter. In the first quarter, TWO SIGMA INVESTMENTS, LP acquired a new stake in Acutus Medical Inc. valued at approximately $21,000. FIRST BUSINESS FINANCIAL SERVICES, INC. acquired a new stake in AFIB for approximately $18,000. AMALGAMATED FINANCIAL CORP. purchased a new stake in AFIB valued at around $6,000 in the second quarter. In total, there are 66 active investors with 42.30% ownership of the company’s stock.
A candlestick chart of Acutus Medical Inc. (NASDAQ: AFIB) showed a price of $1.5300 on Monday morning. During the past 12 months, Acutus Medical Inc. has had a low of $0.48 and a high of $2.49. As of last week, the company has a debt-to-equity ratio of 0.63, a current ratio of 5.10, and a quick ratio of 4.30. The fifty day moving average price for AFIB is $0.9568 and a two-hundred day moving average price translates $0.9857 for the stock.
The latest earnings results from Acutus Medical Inc. (NASDAQ: AFIB) was released for Jun, 2022. According to the Medical Devices Company, earnings per share came in at $0.16, beating analysts’ expectations of -$0.8 by 0.96. This compares to -$0.94 EPS in the same period last year. The company reported revenue of $3.64 million for the quarter, compared to $4.6 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -20.8 percent. For the current quarter, analysts expect AFIB to generate $3.65M in revenue.
Acutus Medical Inc.(AFIB) Company Profile
Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. The company’s product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is headquartered in Carlsbad, California.